Skip to main content
AAN.com
Article
May 1, 1997

Myasthenic crisis
Clinical features, mortality, complications, and risk factors for prolonged intubation

May 1997 issue
48 (5) 1253-1260

Abstract

We retrospectively reviewed the hospital records of 53 patients admitted for 73 episodes of myasthenic crisis at Columbia-Presbyterian Medical Center over a period of 12 years, from 1983 to 1994. Median age at the onset of first crisis was 55 (range, 20 to 82), the ratio of women to men was 21, and the median interval from onset of symptoms to first crisis was 8 months. Infection (usually pneumonia or upper respiratory infection) was the most common precipitating factor (38%), followed by no obvious cause (30%) and aspiration (10%). Twenty-five percent of patients were extubated at 7 days, 50% at 13 days, and 75% at 31 days; the longest crisis exceeded 5 months. Using survival analysis and backward stepwise Cox regression, we identified three independent predictors of prolonged intubation: (1) pre-intubation serum bicarbonate ≥30 mg/dl (p = 0.0004, relative hazard 4.5), (2) peak vital capacity day 1 to 6 post-intubation <25 mYkg (p = 0.001, relative hazard 2.9), and (3) age >50 (p = 0.01, relative hazard 2.4). The proportion of patients intubated longer than 2 weeks was 0% among those with no risk factors, 21% with one risk factor, 46% with two risk factors, and 88% with three risk factors (p = 0.0004). Complications independently associated with prolonged intubation included atelectasis (p = 0.002), anemia treated with transfusion (p = 0.03), Clostridium diffcile infection (p = 0.011, and congestive heart failure (p = 0.03). Three episodes of crisis were fatal, for a mortality rate of 4% (3/73); four additional patients died after extubation. All seven deaths were due to overwhelming medical comorbidity. Over half of those who survived were functionally dependent (home or institutionalized) at discharge. In addition to prospective controlled studies of immuno-therapies, the prevention and treatment of medical complications offers the best opportunity for further improving the outcome of myasthenic crisis.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 48Number 5May 1997
Pages: 1253-1260
PubMed: 9153452

Publication History

Published online: May 1, 1997
Published in print: May 1997

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

C. E. Thomas, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
S. A. Mayer, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
Y. Gungor, BS
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
R. Swarup, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
E. A. Webster, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
I. Chang, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
T. H. Brannagan, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
M. E. Fink, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.
L. P. Rowland, MD
From the Division of Critical Care Neurology, Neurological Institute, New York, NY.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Myasthenia Gravis: Pathophysiology, Diagnosis, and Management, Neuromuscular Diseases - How to Recognize and Treat Them [Working Title], (2024).https://doi.org/10.5772/intechopen.1007603
    Crossref
  2. Myositis in H1N1 Infection Compounds to Myasthenic Crisis, Neurology India, 72, 1, (148-150), (2024).https://doi.org/10.4103/neuroindia.NI_482_19
    Crossref
  3. Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study, Therapeutic Advances in Neurological Disorders, 17, (2024).https://doi.org/10.1177/17562864241226745
    Crossref
  4. The analysis of factors affecting medication adherence in patients with myasthenia gravis: a cross-sectional study, Therapeutic Advances in Neurological Disorders, 17, (2024).https://doi.org/10.1177/17562864231206877
    Crossref
  5. Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis, European Neurology, (1-7), (2024).https://doi.org/10.1159/000540794
    Crossref
  6. Intensive care due to myasthenia gravis: Risk factors and prognosis, European Journal of Neurology, 31, 12, (2024).https://doi.org/10.1111/ene.16522
    Crossref
  7. Risk Stratification and Management of Acute Respiratory Failure in Patients With Neuromuscular Disease, Critical Care Medicine, 52, 11, (1781-1789), (2024).https://doi.org/10.1097/CCM.0000000000006417
    Crossref
  8. Improving Outcome in Severe Myasthenia Gravis and Guillain–Barré Syndrome, Seminars in Neurology, 44, 03, (263-270), (2024).https://doi.org/10.1055/s-0044-1785509
    Crossref
  9. Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis, Scientific Reports, 14, 1, (2024).https://doi.org/10.1038/s41598-024-79918-7
    Crossref
  10. Weaning from mechanical ventilation during myasthenic crisis, a monocentric retrospective study, Scientific Reports, 14, 1, (2024).https://doi.org/10.1038/s41598-024-70373-y
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Share article link

Share